• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Scotiabank initiated coverage on Veracyte with a new price target

    1/5/23 7:28:30 AM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email
    Scotiabank initiated coverage of Veracyte with a rating of Sector Outperform and set a new price target of $33.00
    Get the next $VCYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Veracyte with a new price target

      Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

      3/20/25 7:42:48 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte downgraded by Goldman with a new price target

      Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously

      12/5/24 8:24:30 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on Veracyte with a new price target

      Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00

      11/15/24 8:25:09 AM ET
      $VCYT
      Medical Specialities
      Health Care